DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Edluar (Zolpidem Tartrate) - Summary

 
 



EDLUAR SUMMARY

Edluar (zolpidem tartrate sublingual tablet) is a non-benzodiazepine hypnotic of the imidazopyridine class and is available in 5 mg and 10 mg strength tablets for sublingual administration.

Edluar (zolpidem tartrate sublingual tablets) is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation.

The clinical trials performed with Zolpidem tartrate in support of efficacy were 4-5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment [ see Clinical Studies (14) ].


See all Edluar indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Edluar (Zolpidem)

Progressive Muscle Relaxation for Stress and Insomnia
Source: MedicineNet Healthy Living Specialty [2014.12.01]
Title: Progressive Muscle Relaxation for Stress and Insomnia
Category: Doctor's Views
Created: 5/23/2005 12:00:00 AM
Last Editorial Review: 12/1/2014 12:00:00 AM

Trouble Sleeping? Insomnia May Be Why
Source: MedicineNet Sleep Aids And Stimulants Specialty [2014.12.01]
Title: Trouble Sleeping? Insomnia May Be Why
Category: Doctor's Views
Created: 6/13/2005 12:00:00 AM
Last Editorial Review: 12/1/2014 12:00:00 AM

10 Tips to Avoid Insomnia and Get a Good Night's Sleep
Source: MedicineNet Sleep Aids And Stimulants Specialty [2014.12.01]
Title: 10 Tips to Avoid Insomnia and Get a Good Night's Sleep
Category: Doctor's Views
Created: 6/14/2005 12:00:00 AM
Last Editorial Review: 12/1/2014 12:00:00 AM

Insomnia Pictures Slideshow: 20 Tips for Better Sleep
Source: MedicineNet Sleep Aids And Stimulants Specialty [2014.10.01]
Title: Insomnia Pictures Slideshow: 20 Tips for Better Sleep
Category: Slideshows
Created: 10/1/2014 12:00:00 AM
Last Editorial Review: 10/1/2014 12:00:00 AM

Insomnia
Source: MedicineNet Biorhythms Specialty [2014.07.17]
Title: Insomnia
Category: Diseases and Conditions
Created: 6/6/2005 12:00:00 AM
Last Editorial Review: 7/17/2014 12:00:00 AM

more news >>

Published Studies Related to Edluar (Zolpidem)

Efficacy and safety of a polyherbal sedative-hypnotic formulation NSF-3 in primary insomnia in comparison to zolpidem: a randomized controlled trial. [2013]
insomnia... CONCLUSIONS: NSF-3 is a safe and effective short-term alternative to zolpidem for

Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study. [2013]
to sleep after MOTN awakenings... CONCLUSIONS: 3.5 mg ZST used as needed significantly reduced latency to return to

Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. [2011.07]
CONCLUSIONS: Zolpidem extended-release administered concomitantly with escitalopram for up to 24 weeks was well tolerated and improved insomnia and some sleep-related next-day symptoms and next-day functioning in patients with MDD but did not significantly augment the antidepressant response of escitalopram. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00296179. (c) Copyright 2011 Physicians Postgraduate Press, Inc.

The use of a non-benzodiazepine hypnotic sleep-aid (Zolpidem) in patients undergoing ACL reconstruction: a randomized controlled clinical trial. [2011.05]
PURPOSE: Previous studies have addressed post-operative pain management after ACL reconstruction by examining the use of intra-articular analgesia and/or modification of anesthesia techniques. To our knowledge, however, no previous studies have evaluated the effect of zolpidem on post-operative narcotic requirements, pain, and fatigue in patients undergoing outpatient arthroscopic ACL reconstruction. The purpose of this prospective, blinded, randomized, controlled clinical study was to evaluate the effect of zolpidem on post-operative narcotic requirements, pain, and fatigue in patients undergoing outpatient arthroscopic ACL reconstruction... CONCLUSION: Adding zolpidem to the post-operative medication regimen after arthroscopic ACL reconstruction helps to lower the amount of narcotic pain medication required for adequate analgesia. LEVEL OF EVIDENCE: Randomized controlled clinical trial, Level I.

Zolpidem and zopiclone impair similarly monotonous driving performance after a single nighttime intake in aged subjects. [2011.04]
RATIONALE: Although hypnotics are primarily used by older people, the residual effects the morning after a single nighttime intake of the two most commonly prescribed hypnotics, zolpidem (Zp) and zopiclone (Zc), on older middle-aged drivers have not been evaluated and compared... CONCLUSIONS: This is the first study revealing residual effects of Zp on driving performance in ageing drivers which are similar to that of Zc. Studying the effects of medication in different age ranges appears useful to complete the studies on behavioural-pharmacological effects of medication. To reduce the incidence of driving accidents due to prescription drugs, patients should be warned at the time of treatment initiation that they should avoid driving.

more studies >>

Clinical Trials Related to Edluar (Zolpidem)

A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients [Recruiting]
The purpose of this study is to investigate the efficacy and safety of zolpidem MR (modified release) compared to zolpidem IR (immediate release) in patients with primary insomnia.

Zolpidem CR and Hospitalized Patients With Dementia [Recruiting]
The purpose of this research study is to compare the effectiveness of Zolpidem CR to that of placebo in improving sleep efficiency in people with dementia admitted to the hospital because of their symptoms. You can participate in this study if you have dementia of the Alzheimer's type or vascular dementia. This study involves placebo; a placebo is a tablet that looks exactly like Zolpidem CR, the study drug, but contains no active study drug. We will use placebos to see if the study results are due to the study drug or due to other reasons. Zolpidem CR is also called Ambien CR and is widely available by prescription. Zolpidem CR is approved by the U. S. Food and Drug Administration (FDA) for the short-term treatment of insomnia (trouble falling or staying asleep).

Use of Zolpidem in Parkinson's Disease [Not yet recruiting]
Levodopa treatment is associated with long-term complications. Dopamine deficiency is associated with abnormal activity in certain parts of the brain. Zolpidem may change this abnormal activity and, by doing so, may work in a different way than levodopa to help parkinsonism.

The working hypothesis for this aim is that ZLP is superior to placebo in acutely improving motor symptoms of PD. The investigators will conduct a randomized,controlled, double-blind, cross-over study in 40 patients with PD. Each patient will receive placebo, levodopa and 2 doses of ZLP in a randomized order on 4 different occasions, about one week apart.

A Study to Evaluate Efficacy and Safety of Zolpidem Modified Release Formulation in Insomnia Patients [Recruiting]
The purpose of the study is to investigate the efficacy and safety of zolpidem modified release (MR) tablet using estazolam (Eurodin) as a comparative drug in patients with primary insomnia.

Driving Performance After Middle of the Night Administration of 3.5 mg Zolpidem Tartrate Sublingual Tablet [Recruiting]
A study in healthy volunteers of the next morning driving performance after middle-of-the-night dosing of 3. 5 mg zolpidem tartrate sublingual tablet, a sleep aid. The next morning driving performance will be measured by taking a standardized driving test.

more trials >>


Page last updated: 2014-12-01

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014